BactiQuant A/S

BACTIQ.CO has a market capitalization of DKK 119,319,502 and a price-to-book ratio of 6.91, indicating that the market is valuing the company at a premium to its book value. The company's liquidity position is strong, with cash and equivalents amounting to DKK 17,867,810, and a current ratio of 6.02, suggesting a robust ability to meet short-term obligations. However, the company's operating cash flow is negative at DKK -10,508,000, and free cash flow is also negative at DKK -12,257,120, indicating that the company is not generating positive cash from operations.

Profitability metrics for BACTIQ.CO are negative, with a return on equity of -0.8014 and a return on assets of -0.4928, both significantly below the industry median for the Advanced Medical Equipment & Technology industry. The company's operating income is DKK -12,497,520, and net income is DKK -13,833,120, reflecting a challenging financial performance. The gross profit is also negative at DKK -2,192,640, indicating that the company's cost of goods sold exceeds its revenue.

The company's revenue is concentrated in a single segment, as no segmental breakdown is provided in the available data. There is no information on geographic exposure, but the company's operations are likely centered in its home market, given the lack of international revenue details. The company's capital structure is relatively balanced, with a debt-to-equity ratio of 0.5, indicating that the company is not overly leveraged.

Looking ahead, the company's growth trajectory is uncertain, as there are no specific numeric deltas provided for the current or next fiscal year. The company's revenue history shows a need for improvement, with a total revenue of DKK 8,318,570, which is below the industry median for the Advanced Medical Equipment & Technology industry. The company's capital expenditure is zero, suggesting that it is not investing in new assets or expansion.

The risk assessment for BACTIQ.CO indicates a low liquidity risk and a low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is low, as the number of shares outstanding is the same for both basic and diluted shares, indicating no significant dilution from stock options or convertible securities. The company's valuation adjustments are minimal, suggesting that the market is not applying significant discounts or premiums to the company's financials.

Recent events for BACTIQ.CO include the latest financial filing, which provides the most recent financial data and insights into the company's performance. There are no recent transcripts or other filings that provide additional context on the company's operations or strategic direction.